Octreotide Acetate was first introduced by Novartis Pharmaceuticals Corp in its drug Sandostatin on Oct 21, 1988. Other drugs containing Octreotide Acetate are Sandostatin Lar, Bynfezia Pen, Mycapssa. 14 different companies have introduced drugs containing Octreotide Acetate.

Octreotide Acetate Patents

Given below is the list of patents protecting Octreotide Acetate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Mycapssa	US11141457	Oral octreotide therapy and contraceptive methods	Dec 28, 2040	Chiesi
Mycapssa	US11890316	Oral octreotide therapy and contraceptive methods	Dec 28, 2040	Chiesi
Bynfezia Pen	US11052196	Method of injecting octreotide acetate into the body	Nov 03, 2040	Sun Pharm
Bynfezia Pen	US11246991	Electrolysis-resistant coupling assembly for valves	Nov 03, 2040	Sun Pharm
Bynfezia Pen	US11534553	Method of injecting octreotide acetate into the body	Nov 03, 2040	Sun Pharm
Bynfezia Pen	US10342850	Octreotide injection	May 15, 2038	Sun Pharm
Mycapssa	US10238709	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US10695397	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US11052126	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US11338011	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US11510963	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US11857595	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US12246054	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US12251418	Method of treating diseases	Feb 03, 2036	Chiesi
Mycapssa	US11969471	Pharmaceutical compositions and related methods of delivery	Sep 17, 2029	Chiesi
Mycapssa	US11986529	Pharmaceutical compositions and related methods of delivery	Sep 17, 2029	Chiesi
Mycapssa	US8329198	Pharmaceutical compositions and related methods of delivery	Sep 17, 2029	Chiesi
Mycapssa	US8535695	Pharmaceutical compositions and related methods of delivery	Sep 17, 2029	Chiesi
Mycapssa	US9265812	Pharmaceutical compositions and related methods of delivery	Sep 17, 2029	Chiesi
Mycapssa	US9566246	Pharmaceutical compositions and related methods of delivery	Sep 17, 2029	Chiesi
Sandostatin Lar	US5922338 (Pediatric)	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jan 13, 2017 (Expired)	Novartis
Sandostatin Lar	US5922682 (Pediatric)	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jan 13, 2017 (Expired)	Novartis
Sandostatin Lar	US5922338	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jul 13, 2016 (Expired)	Novartis
Sandostatin Lar	US5922682	Polyol esters, their preparation and use in depot forms of pharmacologically active agents	Jul 13, 2016 (Expired)	Novartis
Sandostatin	US5753618 (Pediatric)	Somatostatin analogue composition and use in treating breast cancer	Nov 19, 2015 (Expired)	Novartis
Sandostatin	US5753618	Somatostatin analogue composition and use in treating breast cancer	May 19, 2015 (Expired)	Novartis
Sandostatin Lar	US5688530 (Pediatric)	Sustained release formulations of water soluble peptides	May 18, 2015 (Expired)	Novartis
Sandostatin Lar	US5639480 (Pediatric)	Sustained release formulations of water soluble peptides	Dec 17, 2014 (Expired)	Novartis
Sandostatin Lar	US5688530	Sustained release formulations of water soluble peptides	Nov 18, 2014 (Expired)	Novartis
Sandostatin Lar	US5639480	Sustained release formulations of water soluble peptides	Jun 17, 2014 (Expired)	Novartis
Sandostatin Lar	US5538739 (Pediatric)	Sustained release formulations of water soluble peptides	Jan 23, 2014 (Expired)	Novartis
Sandostatin Lar	US5538739	Sustained release formulations of water soluble peptides	Jul 23, 2013 (Expired)	Novartis

Add above patents to watchlist

Octreotide Acetate's Family Patents

Full family tree

Octreotide Acetate Generic API Manufacturers

Several generic applications have been filed for Octreotide Acetate. The first generic version for Octreotide Acetate was by West-Ward Pharmaceuticals International Ltd and was approved on Mar 28, 2005. And the latest generic version is by Hainan Shuangcheng Pharmaceuticals Co Ltd and was approved on May 2, 2024.

Given below is the list of companies who have filed for Octreotide Acetate generic, along with the locations of their manufacturing plants worldwide.